PubRank

Richard T Lee

Author PubWeight™ 222.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 2007 8.06
2 Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013 6.35
3 Stem-cell therapy for cardiac disease. Nature 2008 5.75
4 Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004 5.68
5 Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2012 5.56
6 IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007 4.31
7 Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011 3.49
8 Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014 3.37
9 Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 2013 3.35
10 TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 2007 3.27
11 Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014 3.14
12 Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature 2012 3.04
13 Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem 2006 3.02
14 Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011 2.90
15 The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008 2.90
16 Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005 2.89
17 Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest 2005 2.80
18 Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009 2.77
19 Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006 2.75
20 Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol 2005 2.66
21 Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002 2.65
22 Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003 2.62
23 Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 2003 2.54
24 Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004 2.52
25 Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004 2.35
26 Cell mechanics and mechanotransduction: pathways, probes, and physiology. Am J Physiol Cell Physiol 2004 2.32
27 Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 2007 2.31
28 FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci U S A 2006 2.30
29 Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009 2.30
30 Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 2006 2.23
31 Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 2005 2.23
32 The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 2006 2.15
33 Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005 2.12
34 Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation 2004 2.11
35 Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007 2.07
36 Intramyocardial fibroblast myocyte communication. Circ Res 2010 1.98
37 Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008 1.95
38 Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013 1.86
39 Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004 1.82
40 Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 2002 1.79
41 Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem 2007 1.78
42 Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest 2005 1.77
43 Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009 1.74
44 Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem 2009 1.69
45 Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol 2006 1.68
46 Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002 1.67
47 Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res 2002 1.65
48 Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci U S A 2003 1.63
49 Custom design of the cardiac microenvironment with biomaterials. Circ Res 2005 1.63
50 Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. Aging Cell 2008 1.61
51 Identification of mechanically induced genes in human monocytic cells by DNA microarrays. J Hypertens 2002 1.61
52 Biomechanically induced gene iex-1 inhibits vascular smooth muscle cell proliferation and neointima formation. Circ Res 2003 1.57
53 Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012 1.55
54 Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation 2011 1.55
55 Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003 1.52
56 High-resolution whole organ imaging using two-photon tissue cytometry. J Biomed Opt 2007 1.50
57 Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med 2012 1.49
58 A three-dimensional viscoelastic model for cell deformation with experimental verification. Biophys J 2003 1.42
59 Mechanotransduction in cardiac myocytes. Ann N Y Acad Sci 2004 1.40
60 Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation 2004 1.37
61 Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc Natl Acad Sci U S A 2005 1.36
62 Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal 2012 1.36
63 Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 2010 1.36
64 Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells. J Biol Chem 2005 1.33
65 Self-assembling short oligopeptides and the promotion of angiogenesis. Biomaterials 2005 1.33
66 Regeneration of the heart. EMBO Mol Med 2011 1.27
67 Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 2003 1.23
68 Biomaterials to enhance stem cell function in the heart. Circ Res 2011 1.23
69 Cell nuclei spin in the absence of lamin b1. J Biol Chem 2007 1.22
70 Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest 2011 1.21
71 Mechanical control of tissue morphogenesis. Circ Res 2008 1.20
72 The arrestin domain-containing 3 protein regulates body mass and energy expenditure. Cell Metab 2011 1.19
73 Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006 1.19
74 Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 2006 1.16
75 Effect of a cleavage-resistant collagen mutation on left ventricular remodeling. Circ Res 2003 1.16
76 Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002 1.10
77 An expanded family of arrestins regulate metabolism. Trends Endocrinol Metab 2012 1.10
78 Notch signaling regulates cardiomyocyte proliferation during zebrafish heart regeneration. Proc Natl Acad Sci U S A 2014 1.10
79 Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ Heart Fail 2011 1.09
80 Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 2006 1.08
81 Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2011 1.07
82 Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics 2003 1.06
83 An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation 2013 1.06
84 Local delivery of proteins and the use of self-assembling peptides. Drug Discov Today 2007 1.05
85 Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest 2013 1.04
86 Biochemical and mechanical dysfunction in a mouse model of desmin-related myopathy. Circ Res 2009 1.02
87 Genetically engineered resistance for MMP collagenases promotes abdominal aortic aneurysm formation in mice infused with angiotensin II. Lab Invest 2009 1.01
88 Oxidative stress and atherosclerosis. Curr Atheroscler Rep 2005 1.01
89 Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes. Am J Physiol Heart Circ Physiol 2002 1.00
90 Thioredoxin regulates adipogenesis through thioredoxin-interacting protein (Txnip) protein stability. J Biol Chem 2011 0.98
91 Smoking, metalloproteinases, and vascular disease. Arterioscler Thromb Vasc Biol 2005 0.98
92 Protein therapeutics for cardiac regeneration after myocardial infarction. J Cardiovasc Transl Res 2010 0.97
93 Self-assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium. J Biomed Mater Res B Appl Biomater 2008 0.97
94 Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate. Arthritis Rheum 2010 0.96
95 Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol 2004 0.95
96 Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem 2010 0.94
97 Therapeutic vasculogenesis: it takes two. Circ Res 2008 0.93
98 Development biology. Turnover after the fallout. Science 2009 0.92
99 Engineering insulin-like growth factor-1 for local delivery. FASEB J 2008 0.92
100 Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy. Circulation 2003 0.92
101 The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release. J Cell Sci 2010 0.92
102 A low resistance microfluidic system for the creation of stable concentration gradients in a defined 3D microenvironment. Biomed Microdevices 2010 0.90
103 The nuclear membrane and mechanotransduction: impaired nuclear mechanics and mechanotransduction in lamin A/C deficient cells. Novartis Found Symp 2005 0.89
104 Mechanical properties of interphase nuclei probed by cellular strain application. Methods Mol Biol 2009 0.88
105 Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res 2004 0.88
106 Cell stiffness and receptors: evidence for cytoskeletal subnetworks. Am J Physiol Cell Physiol 2004 0.88
107 Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis 2004 0.88
108 Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem 2011 0.88
109 Model systems for cardiovascular regenerative biology. Cold Spring Harb Perspect Med 2013 0.87
110 Salvianolic acid B-vitamin C synergy in cardiac differentiation from embryonic stem cells. Biochem Biophys Res Commun 2009 0.85
111 Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res 2013 0.84
112 Is heart regeneration on the right track? Nat Med 2013 0.83
113 Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol 2011 0.82
114 Time-Saving Benefits of Intravital Staining. J Histotechnol 2008 0.80
115 Thioredoxins, mitochondria, and hypertension. Am J Pathol 2007 0.80
116 Tenth International Conference of the Society for Integrative Oncology Translational Science in Integrative Oncology: from bedside to bench to best practices. Integr Cancer Ther 2014 0.80
117 Cardiovascular regeneration: pushing and pulling on progenitors. Cell Stem Cell 2009 0.80
118 A sensitive chemotaxis assay using a novel microfluidic device. Biomed Res Int 2013 0.79
119 Pathophysiology of atherosclerotic plaque development and rupture: an overview. Semin Vasc Med 2003 0.79
120 A model for mechanotransduction in cardiac muscle: effects of extracellular matrix deformation on autocrine signaling. Ann Biomed Eng 2004 0.79
121 Keep PNUTS in your heart. Circ Res 2013 0.79
122 Torn apart: membrane rupture in muscular dystrophies and associated cardiomyopathies. J Clin Invest 2007 0.78
123 Microbead-based biomimetic synthetic neighbors enhance survival and function of rat pancreatic β-cells. Sci Rep 2013 0.78
124 Vascularization as a potential enemy in valvular heart disease. Circulation 2008 0.78
125 Pericyte progenitors at the crossroads between fibrosis and regeneration. Circ Res 2013 0.78
126 Mechanical stretch and intimal hyperplasia: the missing link? Arterioscler Thromb Vasc Biol 2010 0.77
127 Targeted delivery to cartilage is critical for in vivo efficacy of insulin-like growth factor 1 in a rat model of osteoarthritis. Arthritis Rheumatol 2014 0.77
128 Macrophage-mediated cardiac fibrosis. Circ Res 2004 0.77
129 Dendritic cells in neointima formation: from where did you come, and what are you doing here? J Am Coll Cardiol 2003 0.77
130 Three-dimensional cardiac architecture determined by two-photon microtomy. J Biomed Opt 2009 0.77
131 Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. Tissue Eng Part A 2014 0.77
132 Lessons from lymph: flow-guided vessel formation. Circ Res 2003 0.77
133 Interleukin-33 primes mast cells for activation by IgG immune complexes. PLoS One 2012 0.77
134 Proteins and small molecules for cellular regenerative medicine. Physiol Rev 2013 0.77
135 Endothelial cardiac cell therapy: large-animal studies and the elephant in the room. Circ Res 2012 0.75
136 Directions from Hecate: towards a multi-marker approach for heart failure assessment. Eur J Heart Fail 2011 0.75
137 Patching up the myocardium. Circ Res 2011 0.75
138 Ask the doctor. What's the right treatment if I have a high value on a "heart scan" but no other symptoms? Harv Heart Lett 2003 0.75
139 Ask the doctors. I take the beta blocker propranolol twice a day, once in the morning and again in the evening. The drug information label says I should not take propranolol with alcohol. But I like to have two glasses of wine in the evening. Do I need to change medications, or is there a way to handle the wine and propranolol together? Harv Heart Lett 2013 0.75
140 Ask the doctor. I had a blood test for CRP that came back at 1.9, which my doctor said was on the high side. I had it checked again a few weeks later and it was under 1. What does this mean? Should I have it checked again? Harv Heart Lett 2005 0.75
141 Ask the doctors. There is a long list of drugs and substances that interact with Coumadin (warfarin). Does this mean they make Coumadin more effective, or less effective? Harv Heart Lett 2013 0.75
142 Ask the doctors. I have had high blood pressure for a decade. It has been well controlled with a combination pill that contains two medications. But after I hurt my knee recently, my blood pressure went way up. What should I do? Harv Heart Lett 2013 0.75
143 Ask the doctor. Ultrasound is sometimes used to clean jewelry or break up kidney stones. Can the sound pressure generated by an echocardiogram damage the heart or cause a valve to begin leaking? Harv Heart Lett 2004 0.75
144 Ask the doctors. I recently felt a sudden, sharp pain in my upper back and could not imagine what caused it. Do you have any idea? I was worried it was a heart attack. Harv Heart Lett 2013 0.75
145 Ask the doctor. I have chest pain about once a month. Since it happens so infrequently and has been going on for years, my doctor says I don't need anything other than medicine to keep it under control. Now I need to have two operations, one to fix my cataracts and another to remove part of my colon. Should I start worrying about these heart pains? Harv Heart Lett 2005 0.75
146 Ask the doctors. I used to see a cardiologist for mild high blood pressure, and she performed a cardiac ultrasound, electrocardiogram, and stress test with nuclear imaging every year. I felt reassured when my test results were normal. I had to switch to a new cardiologist, and he routinely does an electrocardiogram, but no other tests. He says I'm doing fine, and that I don't need those tests every year. Am I being neglected? I am not getting as much attention as I used to? Harv Heart Lett 2013 0.75
147 The PEACE study: limiting the role of angiotensin-converting enzyme inhibitors in stable coronary artery disease. Curr Atheroscler Rep 2005 0.75
148 Cardiovascular genomics. Cardiovasc Pathol 2003 0.75
149 Ask the doctor. My doctor told me that I have "low ejection fraction," but I feel fine. How can this be? I thought this was part of heart failure and would make someone feel bad. Should I do anything about it, even though I don't have any symptoms? Harv Heart Lett 2005 0.75
150 When Patients Choose CAM over EBM-How to Negotiate Treatment. Virtual Mentor 2011 0.75
151 Ask the doctors. I am a 78-year-old woman and have atrial fibrillation. My physician prescribed me Coumadin. Last month aspirin was added to my regimen. Is it okay to take both of these drugs together? Harv Heart Lett 2013 0.75
152 Ask the doctors. A friend with heart disease was doing fine until he underwent an operation for colon cancer. He got through the first few days without any problems, but then had a heart attack on the fourth day and nearly died. Why would he have had a heart attack after an operation? I need to have surgery and am wondering how dangerous it will be. Harv Heart Lett 2013 0.75
153 Ask the doctors. I've been taking Coumadin for some time and have begun taking Plavix after having had several stents put in to open blocked arteries. My doctor said Plavix would prevent clots. Isn't that what Coumadin does? Harv Heart Lett 2013 0.75
154 Ask the doctor. I've been seeing ads for a test called IMT that is supposed to spot heart disease and tell how serious it is, even if you don't have any symptoms. Is this for real? Harv Heart Lett 2003 0.75
155 Correction: Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling. PLoS One 2017 0.75
156 Three-dimensional reconstruction of tissues. Curr Protoc Mol Biol 2006 0.75
157 Ask the doctor. How does a beta blocker affect my heart rate and exercise? Harv Heart Lett 2004 0.75
158 Ask the doctors. So many times I have read that people with a BMI greater than 25 are overweight. I'm a man 5 feet, 5 inches tall weighing 168 pounds. My BMI is 28. I have a flat stomach. I lift weights and do push-ups and pull-ups. Does the BMI mislead body builders and athletes by saying we are overweight? Harv Heart Lett 2013 0.75
159 Ask the doctor. I am a 60-year-old man with several risk factors for heart disease. I take Aleve twice a day. Do I still need to take aspirin, or is the Aleve enough? I often take ibuprofen for my headaches or aching back. Now my doctor wants me to start taking aspirin, and she suggested that I ease up on the ibuprofen. Why? Harv Heart Lett 2005 0.75
160 Ask the doctor. Does low-dose Coumadin plus aspirin prevent blood clots? Harv Heart Lett 2004 0.75
161 ST2 and adrenomedullin in heart failure. Heart Fail Clin 2009 0.75
162 Ask the doctor. Should I have a "diamond-tip rooter" procedure to clean out calcium in an artery? Harv Heart Lett 2004 0.75
163 Ask the doctor. I've been told that I have an abnormal T wave. Should I be worried about this? How will it affect my heart health? Harv Heart Lett 2004 0.75